Ally Bridge Group (NY)
Ally Bridge Group (NY) reported 23 stocks worth $77.6M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are NERV (15.6%), PMN (10.5%) and TRAX (7.4%). Compared with Q1 2026, the fund opened new positions in TRAX, AXSM and ASMB, added to NERV and PMN, trimmed EWTX, CTMX and SLDB and sold out of PRAX, CMPS and TARS.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  NERV Minerva Neurosciences Inc | $12.1M | 15.6% | 2.2M | +520K (+31%) | 3 of 8 | |
| 2 |  PMN Promis Neurosciences Inc | $8.2M | 10.5% | 620K | +206K (+50%) | 3 of 8 | |
| 3 |  TRAX First Tracks Biotherapeutics | $5.7M | 7.4% | 284K | New position | 1 of 8 | |
| 4 |  AXSM Axsome Therapeutics Inc | $4M | 5.2% | 16K | New position | 3 of 8 | |
| 5 |  ASMB Assembly Biosciences Inc | $3.8M | 5.0% | 140K | New position | 1 of 8 | |
| 6 |  WHWK Whitehawk Therapeutics Inc | $3.7M | 4.8% | 818K | No change | 7 of 8 | |
| 7 |  EWTX Edgewise Therapeutics Inc | $3.4M | 4.4% | 83K | −78K (−48%) | 6 of 8 | |
| 8 |  CLYM Climb Bio Inc | $3.2M | 4.2% | 249K | New position | 3 of 8 | |
| 9 |  KURA Kura Oncology Inc | $3.2M | 4.1% | 290K | New position | 2 of 8 | |
| 10 |  CTMX Cytomx Therapeutics Inc | $2.9M | 3.8% | 775K | −125K (−14%) | 2 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 PRAX Praxis Precision Medicines I | $10.6M | 33K |
SOLENO THERAPEUTICS INC | $6.7M | 200K |
 CMPS Compass Pathways PLC | $5.8M | 1M |
 TARS Tarsus Pharmaceuticals Inc | $5.7M | 81K |
 ABVX Abivax SA | $3.8M | 34K |
🔒 Free account: see all 8.
Options
valued at the underlying shares
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Ally Bridge Group (NY) 13F FAQ
What does Ally Bridge Group (NY) own?
Ally Bridge Group (NY) reported 23 stocks worth $77.6M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are NERV (15.6%), PMN (10.5%) and TRAX (7.4%). The table above lists every position in the filing (the top 10 without an account).
What did Ally Bridge Group (NY) buy and sell in Q2 2026?
Compared with Q1 2026: 10 new positions, 2 added to, 9 trimmed and 8 sold out. New positions include TRAX, AXSM and ASMB. It sold all of PRAX, CMPS and TARS.
When will Ally Bridge Group (NY) file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Ally Bridge Group (NY)'s portfolio worth?
The Q2 2026 filing reports $77.6M in US stocks ($113M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.